Targeting the Progesterone Receptor in Breast Cancer: Mind the Short Form!

The presurgical window of opportunity trial (WOT) MIPRA provides evidence that neoadjuvant treatment with the prog-esterone receptor (PR) antagonist mifepristone (RU486) may benefit patients with estrogen receptor-positive (ER+) breast cancer characterized by a high ratio of PR-A versus PR-B iso-form (>1.5), suggesting that PR may be targeted in a subset of patients. See related article by Elia et al., p. 866

Automated summary

The presurgical window of opportunity trial (WOT) MIPRA suggests that neoadjuvant treatment with the progesterone receptor (PR) antagonist mifepristone (RU486) may be beneficial for patients with estrogen receptor-positive (ER+) breast cancer, especially those with a high PR-A to PR-B isoform ratio (>1.5), indicating that targeting PR may be effective in a subset of patients.